<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Melphalan: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Melphalan: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Melphalan: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9605" href="/d/html/9605.html" rel="external">see "Melphalan: Drug information"</a> and <a class="drug drug_patient" data-topicid="11391" href="/d/html/11391.html" rel="external">see "Melphalan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709032"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. Monitor hematologic laboratory parameters. Myelosuppression with resulting severe infection, bleeding, or symptomatic anemia may occur with melphalan administered intra-arterially as a percutaneous hepatic perfusion (PHP) (Hepzato). Monitor hematologic laboratory parameters and delay additional cycles of melphalan administered intra-arterially via PHP until blood counts have improved.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Secondary malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Melphalan produces chromosomal aberrations in vitro and in vivo. Melphalan should be considered potentially leukemogenic in humans.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity (injection):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation of melphalan. Discontinue treatment with melphalan for serious hypersensitivity reactions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Administer melphalan under the supervision of a qualified health care provider experienced in the use of cancer chemotherapeutic agents.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Periprocedural complications (Hepzato):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe periprocedural complications, including hemorrhage, hepatocellular injury, and thromboembolic events may occur via hepatic intra-arterial administration of melphalan. Assess patients for these adverse reactions during and for at least 72 hours following administration of melphalan.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk Evaluation and Mitigation Strategy (Hepzato):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Melphalan for intra-arterial infusion via PHP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the Hepzato Kit REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F192382"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alkeran [DSC];</li>
<li>Evomela</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867454"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Alkeran;</li>
<li>TARO-Melphalan</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048451"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</span></li></ul></div>
<div class="block dop drugH1Div" id="F192411"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>
<b>:</b> Intravenous melphalan is available in different formulations. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Melphalan (IV) is associated with a high emetic potential; antiemetics are recommended with IV melphalan to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>). Refer to individual protocols; details concerning dosing in combination regimens should also be consulted; adjust dose based on patient response and weekly blood counts.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="336d736c-0ee0-4c34-a156-2d760c5b5d9e">Hematopoietic stem cell transplantation, conditioning regimen for autologous HSCT</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplantation (HSCT), conditioning regimen for autologous HSCT:</b> Limited data available: <b>Note:</b> Pediatric dosing data based on experience using Alkeran (or corresponding generic) product formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Canete 2009; Oberlin 2006:</i> IV: 140 mg/m<sup>2</sup> 2 days prior to transplantation (combined with busulfan).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pritchard 2005:</i> IV: 180 mg/m<sup>2</sup> (with pre- and posthydration) 12 to 30 hours prior to transplantation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Berthold 2005:</i> IV: 45 mg/m<sup>2</sup>/day for 4 days starting 8 days prior to transplantation (combined with busulfan or etoposide and carboplatin).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">WBC &lt;3,000/mm<sup>3</sup>: Withhold treatment until recovery.</p>
<p style="text-indent:-2em;margin-left:8em;">Platelets &lt;100,000/mm<sup>3</sup>: Withhold treatment until recovery.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Palliative treatment of multiple myeloma: Adjust dose based on blood cell count at the nadir and day of treatment.</p></div>
<div class="block dorp drugH1Div" id="F51159391"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations available; refer to individual protocols. Based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51159392"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; refer individual protocols; based on experience in adult patients, dosage adjustment does not appear to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11306728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11306728'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F192387"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9605" href="/d/html/9605.html" rel="external">see "Melphalan: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> IV melphalan is available as different salt forms and different IV formulations. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Do not substitute melphalan hydrochloride for melphalan flufenamide. Antiemetics are recommended with IV melphalan to prevent nausea and vomiting; IV melphalan is associated with a moderate or high emetic potential (depending on dose). Adjust dose based on patient response and weekly blood counts.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2bb964fb-13ed-42c6-bfab-f7fa02d03357">Amyloidosis, light chain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyloidosis, light chain (off-label use):</b>
<b>Oral:</b> 0.22 mg/kg/day for 4 days every 28 days (in combination with bortezomib and oral dexamethasone) for up to 6 to 8 cycles; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730181'])">Ref</a></span>) <b>or</b> 0.22 mg/kg/day for 4 days every 28 days (in combination with oral dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15070667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15070667'])">Ref</a></span>) <b>or</b> 10 mg/m<sup>2</sup>/day for 4 days every month (in combination with oral dexamethasone) for 12 to 18 treatment cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17855669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17855669'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f603201-62ca-472a-be99-7aaf8559f229">Amyloidosis, light chain, conditioning regimen for autologous hematopoietic cell transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyloidosis, light chain, conditioning regimen for autologous hematopoietic cell transplantation (off-label use): </b>
<b>IV:</b> 200 mg/m<sup>2 </sup>(or 140 mg/m<sup>2</sup> if &gt;65 years of age, left ventricular ejection fraction 40% to 45%, or hematopoietic cell collection ≥2 to &lt;2.5 × 10<sup>6</sup> cells/kg) as a one-time dose prior to hematopoietic cell infusion; some patients received a further reduced dose of 100 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21828140','lexi-content-ref-26443620','lexi-content-ref-14734330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21828140','lexi-content-ref-26443620','lexi-content-ref-14734330'])">Ref</a></span>). Data from a small retrospective analysis demonstrated acceptable safety and efficacy when propylene glycol-free melphalan formulation (Evomela; dose not specified) was used for conditioning prior to autologous hematopoietic cell transplant for light chain amyloidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29679076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29679076'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42cecaf1-ca84-4c2a-aba5-49b2ba92a9e4">Hematopoietic cell transplant, allogeneic, reduced-intensity conditioning regimen for hematologic malignancies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell transplant, allogeneic, reduced intensity conditioning regimen for hematologic malignancies (off-label use): IV:</b> 140 mg/m<sup>2</sup> (in combination with fludarabine) prior to allogeneic hematopoietic cell transplant. In clinical studies, the melphalan dose ranged from 100 to 180 mg/m<sup>2</sup> (administered either as a one-time dose or divided over 2 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25424330','lexi-content-ref-27164061','lexi-content-ref-11157478','lexi-content-ref-30471339','lexi-content-ref-28890406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25424330','lexi-content-ref-27164061','lexi-content-ref-11157478','lexi-content-ref-30471339','lexi-content-ref-28890406'])">Ref</a></span>). Refer to protocols for further details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed25d415-0071-4ad4-a40c-f674136b05b9">Hematopoietic cell transplant, autologous, conditioning regimen for lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell transplant, autologous, conditioning regimen for lymphomas (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">BEAM regimen: <b>IV:</b> 140 mg/m<sup>2</sup> on day -1 prior to autologous hematopoietic cell transplantation on day 0 (in combination with carmustine, etoposide, and cytarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3512114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3512114'])">Ref</a></span>). Data from a small phase II study in lymphoma patients receiving the BEAM conditioning regimen containing the propylene glycol-free melphalan formulation (Evomela; at a dose of 140 mg/m<sup>2</sup> on day -2 prior to transplant) demonstrated acceptable safety and efficacy parameters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27575541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27575541'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">BuMelTT regimen: <b>IV:</b> 50 mg/m<sup>2</sup>/day on days -5 and -4 (total dose 100 mg/m<sup>2</sup>) prior to autologous hematopoietic cell transplantation (in combination with oral busulfan and thiotepa) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9450921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9450921'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GemBuMel regimen: <b>IV:</b> 60 mg/m<sup>2</sup>/day for 2 days (in combination with gemcitabine and busulfan) prior to autologous hematopoietic cell transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22643322','lexi-content-ref-23128322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22643322','lexi-content-ref-23128322'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d5bcca0-516c-49f9-9ff4-3868125ce80c">Hodgkin lymphoma, relapsed or refractory, salvage therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory, salvage therapy (off-label use):</b> Mini-BEAM regimen: <b>IV:</b> 30 mg/m<sup>2</sup> over 15 minutes on day 6 (in combination with carmustine, etoposide, and cytarabine); repeat cycle every 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7844600','lexi-content-ref-11328296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7844600','lexi-content-ref-11328296'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7aa41e1a-2ef4-442c-8825-6fd4129caddd">Multiple myeloma, conditioning regimen prior to hematopoietic cell transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, conditioning regimen prior to hematopoietic cell transplantation</b> (Evomela only): <b>IV:</b> 100 mg/m<sup>2</sup> daily for 2 days on day -3 and day -2 prior to autologous hematopoietic cell transplantation on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26327631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26327631'])">Ref</a></span>). <b>Note:</b> Per the manufacturer, if patients weigh more than 130% of their ideal body weight, body surface area should be calculated using adjusted ideal body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing (propylene glycol-free formulation [Evomela]):</i> Based on limited data: <b>IV:</b> 200 mg/m<sup>2</sup> as a single dose on day -2 prior to autologous hematopoietic cell transplantation on day 0 (followed by filgrastim starting on day +1 after transplant). Data from a small pharmacokinetic study in multiple myeloma patients undergoing autologous hematopoietic cell transplant with propylene glycol-free melphalan conditioning showed acceptable toxicity and efficacy with the single dose regimen, although pharmacokinetic variability between patients was high. Further study is necessary to determine optimal clinical benefit of this dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29751116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29751116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3861b84-e544-4775-8289-431215d2118b">Multiple myeloma, conditioning regimen for autologous hematopoietic cell transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, conditioning regimen for autologous hematopoietic cell transplantation (off-label doses):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 200 mg/m<sup>2</sup> alone 2 days prior to transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16275936','lexi-content-ref-11806971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16275936','lexi-content-ref-11806971'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>140 mg/m<sup>2</sup> 2 days prior to transplantation (combined with busulfan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16275936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16275936'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>140 mg/m<sup>2</sup> 2 days prior to transplantation (combined with total body irradiation [TBI]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11806971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11806971'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>140 mg/m<sup>2</sup> 5 days prior to transplantation (combined with TBI) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16432076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16432076'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d5e175a-b72b-403f-a24e-a302277e849b">Multiple myeloma, previously untreated; transplant ineligible</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, previously untreated; transplant ineligible (off-label dosing/combinations):</b> ≥65 years of age and/or transplant ineligible:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>9 mg/m<sup>2</sup>/day for 4 days (days 1 to 4) every 6 weeks for 9 cycles (in combination with daratumumab/hyaluronidase, bortezomib and prednisone; after cycle 9, daratumumab/hyaluronidase is continued as a single agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33216361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33216361'])">Ref</a></span>)<b> or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>9 mg/m<sup>2</sup>/day for 4 days (days 1 to 4) every 6 weeks for 9 cycles (in combination with daratumumab, bortezomib and prednisone; after cycle 9, daratumumab is continued as a single agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29231133','lexi-content-ref-31836199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29231133','lexi-content-ref-31836199'])">Ref</a></span>)<b> or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 9 mg/m<sup>2</sup>/day for 4 days every 6 weeks (in combination with prednisone <b>or</b> with prednisone and bortezomib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19858394','lexi-content-ref-18753647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19858394','lexi-content-ref-18753647'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>4 mg/m<sup>2</sup>/day for 7 days every 4 weeks (in combination with prednisone <b>or</b> with prednisone and thalidomide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16530576','lexi-content-ref-18505783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16530576','lexi-content-ref-18505783'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 6 mg/m<sup>2</sup>/day for 7 days every 4 weeks (in combination with prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15265788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15265788'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>0.25 mg/kg/day for 4 days every 6 weeks (in combination with prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174762','lexi-content-ref-17920916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174762','lexi-content-ref-17920916'])">Ref</a></span>) <b>or</b> with prednisone and thalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17920916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17920916'])">Ref</a></span>)).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1cb8cf80-34fb-4c1a-98f0-535f0f4864fd">Multiple myeloma, palliative treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, palliative treatment:</b>
<b>Note:</b> Response is gradual; may require repeated courses to realize benefit:</p>
<p style="text-indent:-2em;margin-left:4em;">Usual dose (as described in the manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>6 mg once daily for 2 to 3 weeks initially, followed by up to 4 weeks rest, then a maintenance dose of 2 mg daily as hematologic recovery begins <b>or</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>10 mg daily for 7 to 10 days; institute 2 mg daily maintenance dose after WBC &gt;4,000 cells/mm<sup>3</sup> and platelets &gt;100,000 cells/mm<sup>3</sup> (~4 to 8 weeks); titrate maintenance dose to hematologic response <b>or</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>0.15 mg/kg/day for 7 days, with a 2 to 6 week rest, followed by a maintenance dose of ≤0.05 mg/kg/day as hematologic recovery begins <b>or</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>0.25 mg/kg/day for 4 days (or 0.2 mg/kg/day for 5 days); repeat at 4- to 6-week intervals as ANC and platelet counts return to normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Alkeran: <b>IV:</b> 16 mg/m<sup>2</sup> administered at 2-week intervals for 4 doses, then administer at 4-week intervals after adequate hematologic recovery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7322d635-ec03-41b2-b458-e6daed980825">Ovarian cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer:</b>
<b>Oral:</b> 0.2 mg/kg/day for 5 days, repeat every 4 to 5 weeks <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">Off-label dosing: <b>Oral:</b> 7 mg/m<sup>2</sup>/day in 2 divided doses for 5 days, repeat every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8616766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8616766'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab862c07-37cc-4030-b9cc-3f1915b96db5">Regional perfusion in solid tumors, melanoma and soft tissue sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Regional perfusion in solid tumors, melanoma and soft tissue sarcoma (off-label use): </b>Isolated limb infusion (ILI) protocol: 5 to 10 mg/L of limb volume (maximum: 100 mg) over 20 minutes (in combination with dactinomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19282789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19282789'])">Ref</a></span>) <b>or </b>5 to 10 mg/L of tissue in 400 mL warmed, heparinized NS (in combination with dactinomycin) over 20 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18648882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18648882'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9566908f-decf-47e6-a865-3810728e2c5e">Uveal melanoma, unresectable hepatic metastases</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveal melanoma, unresectable hepatic metastases (Hepzato only): Note:</b> Dose is based on ideal body weight (see manufacturer’s labeling for ideal body weight calculations). Melphalan administered intra-arterially via percutaneous hepatic perfusion (PHP) using the Hepzato Kit should only be administered to patients ≥35 kg (due to size limitations of percutaneous catheterization). Screen patients for history of previous surgery of the bile duct to determine appropriateness of treatment with melphalan administered intra-arterially via PHP. Discontinue oral anticoagulation (warfarin or other anticoagulants) prior to procedure and drugs affecting platelets (eg, aspirin, nonsteroidal anti-inflammatory drugs, or other antiplatelets) 1 week prior to procedure. Discontinue ACE inhibitors, calcium channel blockers, or alpha-1-adrenergic blockers at least 5 half-lives prior to treatment. Ensure patient is euvolemic prior to procedure. Only administer melphalan via percutaneous hepatic perfusion if baseline ANC &gt;2,000/mm<sup>3</sup>, hemoglobin ≥10 g/dL, and platelets ≥100,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Premedication: </i>Administer a proton pump inhibitor the day prior to and the morning of the procedure. Premedicate patients with a history of allergic reaction to iodinated contrast prior to treatment. If antiemetic treatment is required, premedicate with antiemetics in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients ≥35 kg: <b>Intra-arterial infusion via PHP:</b> 3 mg/kg (using ideal body weight; maximum dose: 220 mg) once every 6 to 8 weeks for up to 6 total infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zagar.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zagar.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992096"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer's labeling contains the following adjustment recommendations (for approved dosing levels) based on route of administration:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Moderate to severe renal impairment: Consider a reduced dose initially.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Conditioning regimen for multiple myeloma: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Palliative treatment of multiple myeloma: BUN ≥30 mg/dL: Reduce dose by up to 50%.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Hemodialysis: Melphalan is not removed (to any significant degree) by hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>The following adjustments have also been recommended:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Aronoff 2007: Oral (based on a 6 mg once-daily dose):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 50 mL/minute: Reduce dose to 75% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Reduce dose to 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Administer dose after hemodialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous ambulatory peritoneal dialysis (CAPD): Reduce dose to 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Reduce dose to 75% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Carlson 2005: Oral (for melphalan-prednisone combination therapy; based on a study evaluating toxicity with melphalan dosed at 0.25 mg/kg/day for 4 days/cycle):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;10 to &lt;30 mL/minute: Reduce dose to 75% of normal dose</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≤10 mL/minute: Data is insufficient for a recommendation</p>
<p style="text-indent:-2em;margin-left:4em;">Kintzel 1995:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Adjust dose in the presence of hematologic toxicity</p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 46 to 60 mL/minute: Reduce dose to 85% of normal dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 31 to 45 mL/minute: Reduce dose to 75% of normal dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: Reduce dose to 70% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Badros 2001: IV: Autologous hematopoietic cell transplant (single-agent conditioning regimen; no busulfan or irradiation): Serum creatinine &gt;2 mg/dL: Reduce dose from 200 mg/m<sup>2</sup> over 2 days (as 100 mg/m<sup>2</sup>/day for 2 days) to 140 mg/m<sup>2</sup> given as a single-dose infusion</p>
<p style="text-indent:-2em;margin-left:4em;">International Myeloma Working Group (IMWG) Recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26976420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26976420'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">The IMWG recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &gt;60 mL/minute: Usual dose: 0.15 to 0.25 mg/kg/day for 4 to 7 days</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl 15 to 59 mL/minute: Reduce dose to 75% of usual dose</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &lt;15 mL/minute: Reduce dose to 50% of usual dose</p>
<p style="text-indent:-2em;margin-left:10em;">Hemodialysis: Reduce dose to 50% of usual dose</p>
<p style="text-indent:-2em;margin-left:8em;">IV (high-dose melphalan for autologous hematopoietic cell transplant conditioning regimen):</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &gt;60 mL/minute: Usual dose: 200 mg/m<sup>2</sup> per treatment course</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &lt;15 to 59 mL/minute: Reduce dose to 140 mg/m<sup>2</sup> per treatment course; 100 mg/m<sup>2</sup> (per treatment course) may be appropriate in some patients</p>
<p style="text-indent:-2em;margin-left:10em;">Hemodialysis: Reduce dose to 100 to 140 mg/m<sup>2</sup> per treatment course</p></div>
<div class="block doha drugH1Div" id="F50989311"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV, Oral:</b> Melphalan is hepatically metabolized; however, dosage adjustment does not appear to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11306728','lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11306728','lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F192349"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (74%), hypophosphatemia (49%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (28%), constipation (48%), decreased appetite (49%), diarrhea (93%), dysgeusia (28%), dyspepsia (26%), nausea (90%), stomatitis (28% to 38%; grades 3/4: 5% to 13%), vomiting (64%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≥50%), decreased neutrophils (≥50%), decreased platelet count (≥50%), decreased white blood cell count (≥50%), febrile neutropenia (41%; grades 3/4: 28%), lymphocytopenia (≥50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (38%), fatigue (77%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (48%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Amenorrhea (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (≤2%), hypersensitivity reaction (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: SIADH (Greenbaum-Lefkoe 1985)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hematochezia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Infertility, inhibition of testicular function</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression, bone marrow failure (can be irreversible)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Chromosomal abnormality</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin reaction, alopecia, maculopapular rash, skin necrosis, skin ulceration at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute leukemia, carcinoma, hemolytic anemia, myelodysplastic syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, hepatic sinusoidal obstruction syndrome, hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Flushing sensation, tingling sensation</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis, pulmonary fibrosis</p></div>
<div class="block coi drugH1Div" id="F192365"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Melphalan (IV and oral):</i> Hypersensitivity to melphalan or any component of the formulation; patients whose disease was resistant to prior melphalan therapy (Alkeran only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Melphalan (intra-arterially as a percutaneous hepatic perfusion [PHP]):</i> History of allergies or hypersensitivity to melphalan or any component of the Hepzato Kit; history of hypersensitivity/allergy to heparin or the presence of heparin-induced thrombocytopenia; history of severe allergic reaction to iodinated contrast not controlled by premedication with antihistamines and steroids; active intracranial metastases or brain lesions with a propensity to bleed; liver failure, portal hypertension, or known varices at risk for bleeding; surgery or medical treatment of the liver in the previous 4 weeks; uncorrectable coagulopathy; inability to safely undergo general anesthesia, including active cardiac conditions which include (but are not limited to) unstable coronary syndromes (unstable or severe angina or myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling (IV and oral):</i> Additional contraindications (not in the US labeling): Recent administration of other similar chemotherapeutic agents or radiotherapy; depressed neutrophil and/or platelet counts; concurrent radiotherapy; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F192346"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe bone marrow suppression (including thrombocytopenia, anemia, and neutropenia) may occur, which could result in infection or bleeding; myelosuppression has been shown more with the IV formulation (compared to oral). Myelosuppression is dose-related; myeloablation is expected when used in high doses for conditioning regimens prior to hematopoietic cell transplantation. Do not administer a melphalan-containing conditioning regimen unless the hematopoietic cell product is available for rescue. Use with caution in patients with prior bone marrow suppression, impaired renal function (consider dose reduction), or who have received prior (or concurrent) chemotherapy or irradiation. Myelotoxicity is generally reversible, although irreversible bone marrow failure has been reported. In patients who are candidates for autologous transplantation, avoid melphalan-containing induction regimens if future transplant may be necessary (due to the effects on stem cell reserve). Myelosuppression (including grade 3 or 4) has also been commonly reported with the melphalan administered intra-arterially via percutaneous hepatic perfusion (PHP).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Melphalan is an irritant; local reactions may occur (ESMO/EONS [Perez Fidalgo 2012]). Extravasation may cause local tissue damage. Administration by slow injection into a fast running IV solution into an injection port or via a central line is recommended; do not administer directly into a peripheral vein.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: GI toxicities, including nausea, vomiting, diarrhea, and mucositis are common, particularly when used in high doses for conditioning regimens (the incidence of grade 3 or 4 mucositis was 13% in clinical trials). Nutritional support and/or analgesics may be necessary in patients with severe mucositis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Abnormal liver function tests may occur; hepatitis and jaundice have also been reported. Hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) has been reported with IV melphalan.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis) have occurred in ~2% of patients receiving IV melphalan, usually after multiple treatment cycles. Symptoms may include urticaria, pruritus, edema, skin rashes, tachycardia, bronchospasm, dyspnea, and hypotension. Hypersensitivity may also occur (rarely) with oral melphalan.</p>
<p style="text-indent:-2em;margin-left:4em;">• Periprocedural complications: Hemorrhage, hepatocellular injury, and thromboembolic events have occurred with the administration of melphalan intra-arterially via PHP (Hepzato). Life-threatening or fatal adverse effects may occur; administration of melphalan intra-arterially via PHP requires general anesthesia and extracorporeal bypass of circulation. Patients with abnormal hepatic vascular (especially arterial) or biliary anatomy or gastric acid hypersecretion syndromes may have a higher risk of periprocedural complications or severe adverse events. Reductions in BP, including hypotension, related to the intra-arterial infusion procedure may occur; hypotension may require fluid support or vasopressors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Pulmonary fibrosis (some fatal) and interstitial pneumonitis have been observed with treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Melphalan produces chromosomal abnormalities in vitro and in vivo. Melphalan should be considered potentially leukemogenic in humans. Secondary malignancies (including acute myeloid leukemia, myeloproliferative disease, and carcinoma) have been reported (some patients were receiving combination chemotherapy or radiation therapy); the risk is increased with increased treatment duration and cumulative doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: High-dose melphalan with autologous hematopoietic cell transplant is feasible in patients with multiple myeloma and kidney impairment (Dimopoulos 2016). Prolonged mucositis has occurred when standard melphalan doses were administered to patients with chronic kidney disease (Bodge 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Toxicity may be increased in patients ≥65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Formulations: IV melphalan is available as different salt forms and different IV formulations. Evomela (melphalan for injection) is a lyophilized powder which is reconstituted with normal saline to a 5 mg/mL concentration. Alkeran (melphalan hydrochloride for injection), Hepzato (melphalan hydrochloride for injection), and generic melphalan hydrochloride are also powder formulations which are reconstituted with the supplied diluent (which contains propylene glycol and ethanol) to a 5 mg/mL concentration. Melphalan flufenamide (Pepaxto) is a prodrug of melphalan. Indications for use, product preparation, storage, and dosing differ between salt forms and formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Do not substitute melphalan hydrochloride for melphalan flufenamide.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex (Hepzato only): The double balloon catheter component of the Hepzato Kit delivery system contains natural rubber latex. Use of melphalan through the delivery system is contraindicated in patients with a history of allergy to natural rubber latex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms or diluents may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid vaccination with live vaccines during treatment if immunocompromised.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program (Hepzato only): Melphalan for intra-arterial infusion via PHP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Hepzato Kit REMS Program. Further information is available at 1-833-632-0457.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878539"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F58556107"><span class="drugH1">Product Availability</span>
<p style="text-indent:-2em;margin-left:2em;">Hepzato: FDA approved August 2023; availability anticipated in the 4<sup>th</sup> quarter of 2023. Information pertaining to this product within the monograph is pending revision. Hepzato injection, as a component of the Hepzato Kit, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Consult the prescribing information for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">Melphalan 90 mg/mL multiple-dose vial: FDA approved August 2023; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Melphalan multiple-dose vial is indicated for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. Consult the prescribing information for additional information.</p></div>
<div class="block dosfc drugH1Div" id="F46443778"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Different formulations of intravenous melphalan are available. Alkeran (melphalan hydrochloride for injection) and generic melphalan hydrochloride are reconstituted with the supplied diluent (which contains propylene glycol and ethanol). Evomela (melphalan for injection) is reconstituted with normal saline. Melphalan flufenamide (Pepaxto) is a prodrug of melphalan. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Do not substitute melphalan hydrochloride for melphalan flufenamide.</p></div>
<div class="block foc drugH1Div" id="F192358"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alkeran: 50 mg (1 ea [DSC]) [contains alcohol, usp, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evomela: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alkeran: 2 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg</p></div>
<div class="block geq drugH1Div" id="F192342"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F192367"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Evomela Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1,918.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Melphalan HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $240.00 - $3,007.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Melphalan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $12.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867455"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alkeran: 50 mg (1 ea) [contains alcohol, usp, povidone (polyvinylpyrrolidone), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alkeran: 2 mg</p></div>
<div class="block admp drugH1Div" id="F52613246"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: <b>Note:</b> Melphalan (IV) is associated with a high emetic potential; antiemetics are recommended with IV melphalan to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>). Intravenous melphalan is available in different formulations. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Alkeran: Must be prepared fresh; the time between reconstitution/dilution and administration of parenteral melphalan must be kept to a minimum (manufacturer recommends completing infusion within &lt;60 minutes of reconstitution) because reconstituted and diluted solutions are unstable. Administer by IV infusion typically over 15 to 20 minutes and some centers suggest at a rate not to exceed 10 mg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Evomela: In adults, doses are infused over 30 minutes (conditioning regimen for autologous stem cell transplantation); refer to pediatric-specific protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">Melphalan (IV) is an irritant; local reactions may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Extravasation may cause local tissue damage; administration by slow injection into a fast running IV solution into an injection port or via a central line is recommended; do not administer by direct injection into a peripheral vein.</p></div>
<div class="block adm drugH1Div" id="F192362"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics are recommended with IV melphalan to prevent nausea and vomiting; IV melphalan is associated with a moderate or high emetic potential (depending on dose).</p>
<p style="text-indent:-2em;margin-left:2em;">IV melphalan is available as different salts and different IV formulations. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Do not substitute melphalan hydrochloride for melphalan flufenamide.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Oral:</b> Administer on an empty stomach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12093316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12093316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Alkeran: Due to limited stability, complete administration of IV dose should occur within 60 minutes of reconstitution. Infuse over 15 to 20 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Evomela: Infuse over 30 minutes (conditioning regimen for autologous cell transplantation).</p>
<p style="text-indent:-2em;margin-left:4em;">Melphalan (IV) is an irritant; local reactions may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Extravasation may cause local tissue damage; administration by slow injection into a fast running IV solution into an injection port or via a central line is recommended; do not administer by direct injection into a peripheral vein.</p>
<p style="text-indent:-2em;margin-left:4em;">When administering high-dose melphalan in autologous transplantation, cryotherapy is recommended to prevent oral mucositis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32786044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32786044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Regional perfusion: Technique may vary by institution; consult protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19282789','lexi-content-ref-18648882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19282789','lexi-content-ref-18648882'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intra-arterial infusion via percutaneous hepatic perfusion (Hepzato only): Consult the Hepzato Kit delivery system instructions for use for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). If antiemetic treatment is required, premedicate with antiemetics in subsequent cycles.</p></div>
<div class="block hazard drugH1Div" id="F49132804"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F192375"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Alkeran injection: Store intact vials at 15°C to 30°C (59°F to 86°F). Protect from light. The manufacturer recommends administration be completed within 60 minutes of reconstitution; <b>immediately</b> dilute dose in NS. Do not refrigerate reconstituted solution; precipitation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Evomela injection: Store intact vials at 25°C (77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F). Protect from light (store in original container). The reconstituted solution is stable for 1 hour at room temperature or for 24 hours at 5°C (41°F). Solutions diluted in NS for infusion are stable for 4 hours at room temperature (in addition to the 1 hour at room temperature following reconstitution).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepzato injection: Store intact kit at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F). Protect from light (store in original carton). The delivery system components of the Hepzato Kit may be stored at room temperature. The manufacturer recommends completion of intra-arterial infusion within 60 minutes of reconstitution; <b>immediately</b> dilute dose in NS. Do not refrigerate reconstituted solution; precipitation occurs if stored at 5°C (41°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 2°C to 8°C (36°F to 46°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53567702"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Palliative treatment of multiple myeloma and nonresectable epithelial ovarian carcinoma (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Palliative treatment of multiple myeloma for whom oral therapy is not appropriate (Alkeran: FDA approved in adults); high-dose conditioning regimen for autologous hematopoietic stem cell transplantation (Evomela: FDA approved in adults); treatment of uveal melanoma (as a liver-directed therapy) in patients with unresectable hepatic metastases affecting &lt;50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation (Hepzato: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F192441"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Melphalan may be confused with melphalan flufenamide, Mephyton, Myleran</p>
<p style="text-indent:-2em;margin-left:4em;">Alkeran may be confused with Alferon, Leukeran, Myleran</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Different formulation issues: IV melphalan is available as different salt forms and different IV formulations. Evomela (melphalan for injection) is a lyophilized powder which is reconstituted with normal saline to a 5 mg/mL concentration. Alkeran (melphalan hydrochloride for injection), Hepzato (melphalan hydrochloride for intra-arterial infusion via percutaneous hepatic perfusion), and generic melphalan hydrochloride are also powder formulations which are reconstituted with the supplied diluent (which contains propylene glycol and ethanol) to a 5 mg/mL concentration. Melphalan flufenamide (Pepaxto) is a prodrug of melphalan. Indications for use, product preparation, storage, and dosing differ between salt forms and formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Do not substitute melphalan hydrochloride for melphalan flufenamide.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299659"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F192351"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carmustine: Melphalan may enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CISplatin: May increase the serum concentration of Melphalan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Melphalan may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalidixic Acid: May enhance the adverse/toxic effect of Melphalan. Necrotic enterocolitis has been reported in pediatric patients.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F192378"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food interferes with oral absorption. Management: Administer on an empty stomach.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308155"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use effective contraception during treatment and for 6 months after the last melphalan dose.</p>
<p style="text-indent:0em;margin-top:2em;">Melphalan may damage spermatozoa and testicular tissue, resulting in potential fetal abnormalities. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months after the last melphalan dose.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment with melphalan may suppress ovarian function, leading to amenorrhea. Reversible and irreversible testicular suppression has been reported in patients after melphalan administration. Prior to melphalan treatment, the European Society for Medical Oncology recommends referral to a fertility specialist for patients who wish to preserve fertility (ESMO [Lambertini 2020]).</p></div>
<div class="block pri drugH1Div" id="F3034719"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, melphalan may cause fetal harm if administered during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53567703"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count (at the start of therapy and prior to each subsequent dose), serum electrolytes; serum uric acid; monitor infusion site for redness and irritation </p></div>
<div class="block pha drugH1Div" id="F192345"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Melphalan is an alkylating agent, which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA. Melphalan acts on both resting and rapidly dividing tumor cells.</p></div>
<div class="block phk drugH1Div" id="F192364"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Variable and incomplete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.5 L/kg or 35.5 to 185.7 L/m<sup>2</sup>; Evomela: Penetrates CSF; Alkeran: Low penetration into CSF.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~50% to 92%; primarily to albumin (~40% to 60%), ~20% to alpha<sub>1</sub>-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; chemical hydrolysis to monohydroxymelphalan and dihydroxymelphalan.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Variable; 56% to 93%; exposure is reduced by 36% to 54% with a high-fat meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: IV: ~75 minutes; Oral: 1.5 ± 0.83 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: ~1 to 2 hours; Intra-arterial infusion via percutaneous hepatic perfusion (PHP) (Hepzato only): 0.57 hours (range: 0.05 to 1.18 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Oral: Feces (20% to 50%); urine (~10% as unchanged drug); IV: urine: (6% to 21%); Intra-arterial infusion via PHP: Via isolation of hepatic venous blood flow and filtration by the Hepzato delivery system (HDS); HDS filter efficiency: 82.7%.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: IV: 250 to 325 mL/minute/m<sup>2</sup>.</p></div>
<div class="block phksp drugH1Div" id="F51159446"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: A decrease in estimated creatinine clearance from 100 mL/minute to 30 mL/minute results in 28.2% reduction in clearance for a person with an ideal body weight (IBW) of 70 kg receiving IV melphalan.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: A patient with an IBW of 45 kg receiving IV melphalan has a 28% decrease in clearance relative to a patient with IBW of 70 kg, while a patient with an IBW of 100 kg has a 31% increase in clearance as compared to a patient with an IBW of 70 kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F192369"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alkerana | Eriolan | Melfalan Varifarma | Melfoma</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan sun</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melpha</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan pharmexon</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Phelinun</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Auromelfalan | Melfalan | Melfaseven | Melp spal | Myelkilan | Nozomi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalan | Melphalan ratiopharm | Melphalan sun | Melphalan tillomed | Phelinun</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Egymelan | Melfoma</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alkacel | Alkeran | Melphalan | Melphather</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalan | Melfalan tillomed</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan macure</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan Dci | Melphalan sun | Melphalan tillomed</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalan/Glaxo Smithkline | Melphalan tillomed</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Melfalan Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan tillomed | Sarcolysin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan tillomed</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alkacel | Alkeran | Alphalan | Megval | Melphalaz</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalan sun | Melfalan teva | Melfalan tillomed | Phelinun</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alkacel | Alkeran | Melphalan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalan amarox | Melfalan tillomed | Melfalanhydrochloride teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Megval | Melphalan | Melphalan macure</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan tillomed</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Egymelan | Melfalan | Melfoma | Melphan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alkacel | Alkeran</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alkacel | Alkeran | Megval | Melphalan tillomed</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Evomela | Melphalan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalano teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Melfalan bioteng</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan | Phelinun</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Megval | Melphalan nativ</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Megval</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalan sun | Melphalan macure</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melfalan teva | Melphalan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphalan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alkacel | Alkeran | Eriolan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melphather</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Melp spal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alkeran</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Alkeran | Recrom | Zalcaren and sterile diluent for zalcaren</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-498715">
<a name="498715"></a>Alberts DS, Chang SY, Chen HS, et al, “Oral Melphalan Kinetics,” <i>Clin Pharmacol Ther</i>, 1979, 26(6):737-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/498715/pubmed" id="498715" target="_blank">498715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alkeran.2">
<a name="Alkeran.2"></a>Alkeran (melphalan injection) [prescribing information]. Research Triangle Park, NJ: GlaxoSmithKline; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alkeran.1">
<a name="Alkeran.1"></a>Alkeran (melphalan) tablets, powder for solution for injection [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alkeran.3">
<a name="Alkeran.3"></a>Alkeran (melphalan tablets) [prescribing information]. Research Triangle Park, NJ: GlaxoSmithKline; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3512114">
<a name="3512114"></a>Anderson CC, Goldstone AH, Souhami RL, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. <i>Cancer Chemother Pharmacol</i>. 1986;16(2):170-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/3512114/pubmed" id="3512114" target="_blank">3512114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29679076">
<a name="29679076"></a>Badar T, Hari P, Chhabra S, et al. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplant.</i> 2018;53(9):1210-1213. doi:10.1038/s41409-018-0178-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/29679076/pubmed" id="29679076" target="_blank">29679076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11564069">
<a name="11564069"></a>Badros A, Barlogie B, Siegel E, et al, “Results of Autologous Stem Cell Transplant in Multiple Myeloma Patients With Renal Failure,” <i>Br J Haematol</i>, 2001, 114(4):822-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/11564069/pubmed" id="11564069" target="_blank">11564069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16432076">
<a name="16432076"></a>Barlogie B, Kyle RA, Anderson KC, et al, “Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321,” <i>J Clin Oncol</i>, 2006, 24(6):929-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/16432076/pubmed" id="16432076" target="_blank">16432076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25424330">
<a name="25424330"></a>Baron F, Labopin M, Peniket A, et al. Reduced-intensity conditioning with fludarabine and busulfant versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i>. 2015;121(7):1048-1055. doi:10.1002/cncr.29163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/25424330/pubmed" id="25424330" target="_blank">25424330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16129365">
<a name="16129365"></a>Berthold F, Boos J, Burdach S, et al, “Myeloablative Megatherapy With Autologous Stem-Cell Rescue Versus Oral Maintenance Chemotherapy as Consolidation Treatment in Patients With High-Risk Neuroblastoma: A Randomised Controlled Trial,” <i>Lancet Oncol</i>, 2005, 6(9):649-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/16129365/pubmed" id="16129365" target="_blank">16129365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24565993">
<a name="24565993"></a>Bodge MN, Reddy S, Thompson MS, Savani BN. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. <i>Biol Blood Marrow Transplant</i>. 2014;20(7):908-919.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/24565993/pubmed" id="24565993" target="_blank">24565993</a>]</span>
<span class="doi">10.1016/j.bbmt.2014.02.013</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19282789">
<a name="19282789"></a>Brady MS, Brown K, Patel A, Fisher C, Marx W. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. <i>Melanoma Res.</i> 2009;19(2):106-111. doi:10.1097/CMR.0b013e32832985e3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/19282789/pubmed" id="19282789" target="_blank">19282789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19171715">
<a name="19171715"></a>Canete A, Gerrard M. Rubie H, et al, “Poor Survival for Infants with MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society for Paediatric Oncology European Neuroblastoma Experience,” <i>J Clin Oncol</i>, 2009, 27(7):1014-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/19171715/pubmed" id="19171715" target="_blank">19171715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15725084">
<a name="15725084"></a>Carlson K, Hjorth M, Knudsen LM, et al, “Toxicity in Standard Melphalan-Prednisone Therapy Among Myeloma Patients With Renal Failure - A Retrospective Analysis and Recommendations for Dose Adjustment,” <i>Br J Haematol</i>, 2005, 128(5):631-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/15725084/pubmed" id="15725084" target="_blank">15725084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27575541">
<a name="27575541"></a>Cashen AF, Fletcher T, Ceriotti C, et al. Phase II study of propylene glycol-free melphalan combined with carmustine, etoposide, and cytarabine for myeloablative conditioning in lymphoma patients undergoing autologous stem cell transplantation. <i>Biol Blood Marrow Transplant</i>. 2016;22(12):2155-2158. doi: 10.1016/j.bbmt.2016.08.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/27575541/pubmed" id="27575541" target="_blank">27575541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33216361">
<a name="33216361"></a>Chari A, Rodriguez-Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study. <i>Br J Haematol</i>. 2021;192(5):869-878. doi:10.1111/bjh.16980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/33216361/pubmed" id="33216361" target="_blank">33216361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21828140">
<a name="21828140"></a>Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. <i>Blood.</i> 2011;118(16):4346-4352. doi:10.1182/blood-2011-01-330738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/21828140/pubmed" id="21828140" target="_blank">21828140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7844600">
<a name="7844600"></a>Colwill R, Crump M, Couture F, et al, “Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin’s Disease Before Intensive Therapy or Autologous Bone Marrow Transplantation,” <i>J Clin Oncol</i>, 1995, 13(2):396-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/7844600/pubmed" id="7844600" target="_blank">7844600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27164061">
<a name="27164061"></a>Damlaj M, Alkhateeb HB, Hefazi M, et al. Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing. <i>Biol Blood Marrow Transplant.</i> 2016;22(8):1431-1439. doi:10.1016/j.bbmt.2016.04.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/27164061/pubmed" id="27164061" target="_blank">27164061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29751116">
<a name="29751116"></a>Dhakal B, D'Souza A, Lakshman A, et al. Pharmacokinetics of high-dose propylene glycol-free melphalan in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. <i>Biol Blood Marrow Transplant</i>. 2018;24(8):1610-1614. doi: 10.1016/j.bbmt.2018.04.028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/29751116/pubmed" id="29751116" target="_blank">29751116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19858394">
<a name="19858394"></a>Dimopoulos MA, Richardson PG, Schlag R, et al, “VMP (Bortezomib, Melphalan, and Prednisone) is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study,” <i>J Clin Oncol</i>, 2009, 27(36):6086-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/19858394/pubmed" id="19858394" target="_blank">19858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976420">
<a name="26976420"></a>Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016;34(13):1544-1557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/26976420/pubmed" id="26976420" target="_blank">26976420</a>]</span>
<span class="doi">10.1200/JCO.2015.65.0044</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32786044">
<a name="32786044"></a>Elad S, Cheng KKF, Lalla RV, et al; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i>. 2020;126(19):4423-4431. doi:10.1002/cncr.33100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/32786044/pubmed" id="32786044" target="_blank">32786044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Evomela.1">
<a name="Evomela.1"></a>Evomela (melphalan) [prescribing information]. East Windsor, NJ: Acrotech Biopharma Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17920916">
<a name="17920916"></a>Facon T, Mary JY, Hulin C, et al, “Melphalan and Prednisone Plus Thalidomide Versus Melphalan and Prednisone Alone or Reduced-Intensity Autologous Stem Cell Transplantation in Elderly Patients With Multiple Myeloma (IFM 99-06): A Randomised Trial,” <i>Lancet</i>, 2007, 370(9594):1209-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/17920916/pubmed" id="17920916" target="_blank">17920916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174762">
<a name="16174762"></a>Facon T, Mary JY, Pegourie B, et al, “Dexamethasone-Based Regimens versus Melphalan-Prednisone for Elderly Multiple Myeloma Patients Ineligible for High-Dose Therapy,” <i>Blood</i>, 2006, 107(4):1292-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/16174762/pubmed" id="16174762" target="_blank">16174762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16275936">
<a name="16275936"></a>Fermand JP, Katsahian S, Divine M, et al, “High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe,” <i>J Clin Oncol</i>, 2005, 23(36):9227-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/16275936/pubmed" id="16275936" target="_blank">16275936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11157478">
<a name="11157478"></a>Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <i>Blood</i>. 2001;97(3):631-637. doi:10.1182/blood.v97.3.631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/11157478/pubmed" id="11157478" target="_blank">11157478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3965085">
<a name="3965085"></a>Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB, Rohrbaugh TM, Meadows AT. Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. <i>Cancer</i>. 1985;55(1):44-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/3965085/pubmed" id="3965085" target="_blank">3965085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26327631">
<a name="26327631"></a>Hari P, Aljitawi OS, Arce-Lara C, et al. A phase IIb, multicenter, open-label, safety, and efficacy study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation. <i>Biol Blood Marrow Transplant</i>. 2015;21(12):2100-2105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/26327631/pubmed" id="26327631" target="_blank">26327631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Delcath.1">
<a name="Delcath.1"></a>Hepzato (melphalan) [prescribing information]. Queensbury, NY: Delcath Systems Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17855669">
<a name="17855669"></a>Jaccard A, Moreau P, Leblond V, et al, “High-Dose Melphalan versus Melphalan Plus Dexamethasone for AL Amyloidosis,” <i>N Engl J Med</i>, 2007, 357(11):1083-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/17855669/pubmed" id="17855669" target="_blank">17855669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30471339">
<a name="30471339"></a>Jain T, Alahdab F, Firwana B, et al. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: a systematic review and meta-analysis. <i>Biol Blood Marrow Transplant.</i> 2019;25(4):728-733. doi:10.1016/j.bbmt.2018.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/30471339/pubmed" id="30471339" target="_blank">30471339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32730181">
<a name="32730181"></a>Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. <i>J Clin Oncol</i>. 2020;38(28):3252-3260. doi:10.1200/JCO.20.01285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/32730181/pubmed" id="32730181" target="_blank">32730181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28890406">
<a name="28890406"></a>Kawamura K, Kako S, Mizuta S, et al. Comparison of conditioning with fludarabine/busulfan and flludarabine/melphalan in allogeneic transplantation recipients 50 years or older. <i>Biol Blood Marrow Transplant.</i> 2017;23(12):2079-2087. doi:10.1016/j.bbmt.2017.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/28890406/pubmed" id="28890406" target="_blank">28890406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17236223">
<a name="17236223"></a>Keefe DM, Schubert MM, Elting LS, et al, "Updated Clinical Practice Guidelines for the Prevention and Treatment of Mucositis," <i>Cancer</i>, 2007, 109(5):820-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/17236223/pubmed" id="17236223" target="_blank">17236223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11306728">
<a name="11306728"></a>King PD and Perry MC, “Hepatotoxicity of Chemotherapy,” <i>Oncologist</i>, 2001, 6(2):162-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/11306728/pubmed" id="11306728" target="_blank">11306728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE and Dorr RT, “Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,” <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467711">
<a name="18467711"></a>Lazarus HM, Phillips GL, Herzig RH, et al, "High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later," <i>J Clin Oncol</i>, 2008, 26(14):2240-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/18467711/pubmed" id="18467711" target="_blank">18467711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11328296">
<a name="11328296"></a>Martin A, Fernandez-Jimenez MC, Caballero MD, et al, “Long-Term Follow-Up in Patients Treated with Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin’s Disease,” <i>Br J Haematol</i>, 2001, 113(1):161-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/11328296/pubmed" id="11328296" target="_blank">11328296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31836199">
<a name="31836199"></a>Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet.</i> 2020;395(10218):132-141. doi:10.1016/S0140-6736(19)32956-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/31836199/pubmed" id="31836199" target="_blank">31836199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29231133">
<a name="29231133"></a>Mateos MV, Dimopoulos MA, Cavo M, et al; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. <i>N Engl J Med</i>. 2018;378(6):518-528. doi: 10.1056/NEJMoa1714678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/29231133/pubmed" id="29231133" target="_blank">29231133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18648882">
<a name="18648882"></a>Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. <i>Ann Surg Oncol</i>. 2008;15(10):2749-2756. doi:10.1245/s10434-008-0045-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/18648882/pubmed" id="18648882" target="_blank">18648882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11806971">
<a name="11806971"></a>Moreau P, Facon T, Attal M, et al, “Comparison of 200 mg/m<sup>2</sup> Melphalan and 8 Gy Total Body Irradiation Plus 140 mg/m<sup>2</sup> Melphalan as Conditioning Regimens for Peripheral Blood Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of the Intergroupe Francophone du Myélome 9502 Randomized Trial,” <i>Blood</i>, 2002, 99(3):731-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/11806971/pubmed" id="11806971" target="_blank">11806971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17324241">
<a name="17324241"></a>Nath CE, Shaw PJ, Montgomery K, et al, “Population Pharmacokinetics of Melphalan in Pediatric Blood or Marrow Transplant Recipients,” <i>Br J Clin Pharmacol</i>, 2007, 64(2):151-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/17324241/pubmed" id="17324241" target="_blank">17324241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20573084">
<a name="20573084"></a>Nath CE, Shaw PJ, Trotman J, et al, “Population Pharmacokinetics of Melphalan in Patients With Multiple Myeloma Undergoing High Dose Therapy,” <i>Br J Clin Pharmacol</i>, 2010, 69(5):484-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/20573084/pubmed" id="20573084" target="_blank">20573084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23128322">
<a name="23128322"></a>Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. <i>Biol Blood Marrow Transplant.</i> 2013;19(3):410-417. doi:10.1016/j.bbmt.2012.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/23128322/pubmed" id="23128322" target="_blank">23128322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22643322">
<a name="22643322"></a>Nieto Y, Thall P, Valdez B, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. <i>Biol Blood Marrow Transplant.</i> 2012;18(11):1677-1686. doi:10.1016/j.bbmt.2012.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/22643322/pubmed" id="22643322" target="_blank">22643322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16921053">
<a name="16921053"></a>Oberlin O, Rey A, Desfachelles AS, et al, "Impact of High-Dose Busulfan Plus Melphalan as Consolidation in Metastatic Ewing Tumors: A Study by the Société Française des Cancers de l'Enfant," <i>J Clin Oncol</i>, 2006, 24(24):3997-4002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/16921053/pubmed" id="16921053" target="_blank">16921053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18376282">
<a name="18376282"></a>Ozkaynak MF, Sahdev I, Gross TG, et al, "A Pilot Study of Addition of Amifostine to Melphalan, Carboplatin, Etoposide, and Cyclophosphamide With Autologous Hematopoietic Stem Cell Transplantation in Pediatric Solid Tumors - A Pediatric Blood and Marrow Transplant Consortium Study," <i>J Pediatr Hematol Oncol</i>, 2008, 30(3):204-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/18376282/pubmed" id="18376282" target="_blank">18376282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15070667">
<a name="15070667"></a>Palladini G, Perfetti V, Obici L, et al, “Association of Melphalan and High-Dose Dexamethasone is Effective and Well Tolerated in Patients With AL (Primary) Amyloidosis Who are Ineligible for Stem Cell Transplantation,” <i>Blood</i>, 2004, 103(8):2936-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/15070667/pubmed" id="15070667" target="_blank">15070667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16530576">
<a name="16530576"></a>Palumbo A, Bringhen S, Caravita T, et al, “Oral Melphalan and Prednisone Chemotherapy Plus Thalidomide Compared With Melphalan and Prednisone Alone in Elderly Patients With Multiple Myeloma: Randomised Controlled Trial,” <i>Lancet</i>, 2006, 367(9513):825-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/16530576/pubmed" id="16530576" target="_blank">16530576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18505783">
<a name="18505783"></a>Palumbo A, Bringhen S, Liberati AM, et al, “Oral Melphalan, Prednisone, and Thalidomide in Elderly Patients With Multiple Myeloma: Updated Results of a Randomized Controlled Trial,” <i>Blood</i>, 2008, 112(8):3107-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/18505783/pubmed" id="18505783" target="_blank">18505783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15265788">
<a name="15265788"></a>Palumbo A, Bringhen S, Petrucci MT, et al, “Intermediate-Dose Melphalan Improves Survival of Myeloma Patients Aged 50 to 70: Results of a Randomized Controlled Trial,” <i>Blood</i>, 2004, 104(10):3052-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/15265788/pubmed" id="15265788" target="_blank">15265788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):vii167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7856585">
<a name="7856585"></a>Pinguet F, Martel P, Rouanet P, et al, “Effect of Sodium Chloride Concentration and Temperature on Melphalan Stability During Storage and Use,” <i>Am J Hosp Pharm</i>, 1994, 51(21):2701-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/7856585/pubmed" id="7856585" target="_blank">7856585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15546135">
<a name="15546135"></a>Pritchard J, Cotterill SJ, Germond SM, et al, “High Dose Melphalan in the Treatment of Advanced Neuroblastoma: Results of a Randomised Trial (ENSG-1) by the European Neuroblastoma Study Group,” <i>Pediatr Blood Cancer</i>, 2005, 44(4):348-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/15546135/pubmed" id="15546135" target="_blank">15546135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20555089">
<a name="20555089"></a>Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/20555089/pubmed" id="20555089" target="_blank">20555089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18753647">
<a name="18753647"></a>San Miguel JF, Schlag R, Khuageva NK, et al, “Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma,” <i>New Engl J Med</i>, 2008, 359(9):906-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/18753647/pubmed" id="18753647" target="_blank">18753647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443620">
<a name="26443620"></a>Sanchorawala V, Sun F, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. <i>Blood.</i> 2015;126(20):2345-2347. doi:10.1182/blood-2015-08-662726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/26443620/pubmed" id="26443620" target="_blank">26443620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9450921">
<a name="9450921"></a>Schiffman K, Buckner CD, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. <i>Biol Blood Marrow Transplant</i>. 1997;3(5):261-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/9450921/pubmed" id="9450921" target="_blank">9450921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12093316">
<a name="12093316"></a>Schmidt LE, Dalhoff K. Food-drug interactions. <i>Drugs</i>. 2002;62(10):1481-1502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/12093316/pubmed" id="12093316" target="_blank">12093316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10578165">
<a name="10578165"></a>Schuh A, Dandridge J, Haydon P, et al, “Encephalopathy Complicating High-Dose Melphalan,” <i>Bone Marrow Transplant</i>, 1999, 24(10):1141-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/10578165/pubmed" id="10578165" target="_blank">10578165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16097572">
<a name="16097572"></a>Seddon BM, Cassoni AM, Galloway MJ, et al, “Fatal Radiation Myelopathy After High-Dose Busulfan and Melphalan Chemotherapy and Radiotherapy for Ewing’s Sarcoma: A Review of the Literature and Implications for Practice,” <i>Clin Oncol</i>, 2005, 17(5):385-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/16097572/pubmed" id="16097572" target="_blank">16097572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14734330">
<a name="14734330"></a>Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL-amyloidosis: an 8-year study. <i>Ann Intern Med.</i> 2004;140(2):85-93. doi:10.7326/0003-4819-140-2-200401200-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/14734330/pubmed" id="14734330" target="_blank">14734330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8616766">
<a name="8616766"></a>Wadler S, Yeap B, Vogl S, et al, “Randomized Trial of Initial Therapy With Melphalan Versus Cisplatin-Based Combination Chemotherapy in Patients With Advanced Ovarian Carcinoma: Initial and Long Term Results -- Eastern Cooperative Oncology Group Study E2878,” <i>Cancer</i>, 1996, 77(40):733-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/8616766/pubmed" id="8616766" target="_blank">8616766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zagar.1">
<a name="Zagar.1"></a>Zagar J, Orlogg, M, Ferrucci PF, et al. FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). <i>J Clin Oncol</i>. 2022;40 (16_suppl):9510.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melphalan-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12579 Version 345.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
